CureVac Past Earnings Performance
Past criteria checks 3/6
CureVac has been growing earnings at an average annual rate of 15.8%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 50.1% per year. CureVac's return on equity is 27.9%, and it has net margins of 34.5%.
Key information
15.82%
Earnings growth rate
106.57%
EPS growth rate
Biotechs Industry Growth | 17.04% |
Revenue growth rate | 50.08% |
Return on equity | 27.94% |
Net Margin | 34.50% |
Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
The Strong Earnings Posted By CureVac (NASDAQ:CVAC) Are A Good Indication Of The Strength Of The Business
May 27
GSK Milestones And Tech Focus Will Shape Oncology Amid Risks
Strategic focus on innovation and R&D in oncology and infectious diseases positions CureVac for potential high-growth opportunities and revenue enhancement.CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth
May 01CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions
Mar 28CureVac: Latest GBM Data Bodes Well For Next Program Check Point
Jan 08Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25%
Jan 04CureVac: Back To Square One
Oct 08CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk
Sep 16CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price
Aug 03We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
Jul 05CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas
Jul 04Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking
Jun 01We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20CureVac: No Momentum In Sight
Mar 08What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
Aug 26CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 14Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
May 01Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
Apr 29An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Jan 08CureVac BV reports Q2 results
Aug 18CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
Jul 05Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
May 02A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Oct 28CureVac: Wait For Concrete News Before Investing
Sep 01An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Jun 13Revenue & Expenses Breakdown
How CureVac makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 25 | 524 | 181 | 72 | 163 |
31 Dec 24 | 535 | 162 | 74 | 153 |
30 Sep 24 | 304 | -77 | 84 | 138 |
30 Jun 24 | 66 | -278 | 85 | 116 |
31 Mar 24 | 59 | -273 | 92 | 119 |
31 Dec 23 | 54 | -260 | 96 | 116 |
30 Sep 23 | 43 | -302 | 95 | 110 |
30 Jun 23 | 38 | -301 | 103 | 95 |
31 Mar 23 | 50 | -291 | 106 | 76 |
31 Dec 22 | 67 | -249 | 107 | 63 |
30 Sep 22 | 97 | -122 | 100 | 566 |
30 Jun 22 | 115 | -219 | 103 | 602 |
31 Mar 22 | 117 | -313 | 105 | 722 |
31 Dec 21 | 103 | -412 | 102 | 816 |
30 Sep 21 | 68 | -468 | 102 | 322 |
30 Jun 21 | 44 | -361 | 81 | 308 |
31 Mar 21 | 56 | -219 | 64 | 208 |
31 Dec 20 | 49 | -129 | 54 | 114 |
30 Sep 20 | 50 | -107 | 56 | 89 |
31 Mar 20 | 17 | -102 | 56 | 43 |
31 Dec 19 | 17 | -100 | 51 | 43 |
31 Dec 18 | 13 | -71 | 26 | 42 |
Quality Earnings: CVAC has a high level of non-cash earnings.
Growing Profit Margin: CVAC became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CVAC has become profitable over the past 5 years, growing earnings by 15.8% per year.
Accelerating Growth: CVAC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CVAC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (21.7%).
Return on Equity
High ROE: CVAC's Return on Equity (27.9%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/29 06:21 |
End of Day Share Price | 2025/05/29 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CureVac N.V. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Alec Stranahan | BofA Global Research |
Douglas Buchanan | Citizens JMP Securities, LLC |
Martin Auster | Credit Suisse |